Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.1	28.09.2024	1228550-00022	Date of first issue: 18.01.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier				
	Trade name	:	Abamectin Liquid Formulation	
1.2	Relevant identified uses of t	he s	ubstance or mixture and uses advised against	
	Use of the Sub- stance/Mixture	:	Veterinary product	
	Recommended restrictions on use	:	Not applicable	
1.3	Details of the supplier of the	saf	ety data sheet	
	Company	:	MSD	
			Kilsheelan	
			Clonmel Tipperary, IE	
	Telephone	:	353-51-601000	
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com	

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4 Specific target organ toxicity - repeated exposure, Category 2 Short-term (acute) aquatic hazard, Category 1 Long-term (chronic) aquatic hazard, Category 1 H332: Harmful if inhaled. H373: May cause damage to organs through prolonged or repeated exposure. H400: Very toxic to aquatic life.

H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version 6.1	Revision Date: 28.09.2024	-	DS Number: 228550-0002		Date of last issue: 06.04.2024 Date of first issue: 18.01.2017
Signa	al word	:	Warning		
Haza	rd statements	:	H332 H373	May ca	ul if inhaled. ause damage to organs through prolonged eated exposure.
			H410	•	oxic to aquatic life with long lasting effects.
Preca	autionary statements	:	Prevention	n:	
			P271 P273		nly outdoors or in a well-ventilated area. release to the environment.
			Response:	:	
			P304 + P34	air and	2 IF INHALED: Remove person to fresh keep comfortable for breathing. Call a N CENTER/ doctor if you feel unwell.
			P314 P391	Get m	edical advice/ attention if you feel unwell. t spillage.

Hazardous components which must be listed on the label:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.


Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)	
abamectin (combination of aver- mectin B1a and avermectin B1b) (ISO)	71751-41-2 606-143-00-0	Acute Tox. 2; H300 Acute Tox. 1; H330 Acute Tox. 3; H311 Repr. 2; H361fd STOT RE 1; H372 (Central nervous system) Aquatic Acute 1;	>= 1 - < 2.5	





Abamectin Liquid Formulation

Version 6.1	Revision Date: 28.09.2024	SDS Number: 1228550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017
			H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000
			specific concentration limit STOT RE 1; H372 >= 5 % STOT RE 2; H373 0.5 - < 5 %

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice :	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders :	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled :	If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.
In case of skin contact :	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact :	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed :	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.1	28.09.2024	1228550-00022	Date of first issue: 18.01.2017

4.2 Most important symptoms and effects, both acute and delayed

Risks	: Harmful if inhaled.
	May cause damage to organs through prolonged or repeated
	exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment	: Treat sy	mptomatically and supportively.
-----------	------------	---------------------------------

SECTION 5: Firefighting measures

5.1 Extinguishing media

5.3

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical	
Unsuitable extinguishing	:	None known.	

Unsuitable extinguishing	:	None known
media		

5.2 Special hazards arising from the substance or mixture

	opecial hazards ansing nom the substance of mixture				
	Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.		
	Hazardous combustion prod- ucts	:	Carbon oxides		
; ,	Advice for firefighters				
	Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.		
	Specific extinguishing meth-	:	Use extinguishing measures that are appropriate to local cir-		

ods	cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
	Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment.
	Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions	:	Avoid release to the environment.
---------------------------	---	-----------------------------------

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Abamectin Liquid Formulation

Version 6.1	Revision Date: 28.09.2024	SDS Number: 1228550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017		
		Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.			
6.3 Metho	ds and material for co	ontainment and clear	ning up		
Methods for cleaning up		For large spills, ment to keep m be pumped, sto Clean up remain bent. Local or nationa posal of this ma employed in the mine which regu	ert absorbent material. provide dyking or other appropriate contain- aterial from spreading. If dyked material can re recovered material in appropriate container. hing materials from spill with suitable absor- al regulations may apply to releases and dis- terial, as well as those materials and items cleanup of releases. You will need to deter- ulations are applicable.		

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	 Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety
	practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	 If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the



Commission Regulation (EU) 2020/878

Abamectin Liquid Formulation

Versio 6.1	n Revision Date: 28.09.2024	SDS Number: 1228550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017		
		use of administra	ative controls.		
7.2 Co	onditions for safe storage,	including any incon	npatibilities		
Requirements for storage areas and containers		Keep in a cool, v	Keep in properly labelled containers. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.		
A	dvice on common storage	Strong oxidizing	ostances and mixtures		
•	ecific end use(s) pecific use(s)	: No data availabl	e		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
abamectin (combi- nation of avermec- tin B1a and aver- mectin B1b) (ISO)	71751-41-2	TWA	15 μg/m3 (OEB 3)	Internal
		Wipe limit	150 μg/100 cm²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Glycerides, mixed decanoyl and oc- tanoyl	Workers	Inhalation	Long-term systemic effects	177.79 mg/m3
	Workers	Skin contact	Long-term systemic effects	25.21 mg/kg bw/day
Consumers		Inhalation	Long-term systemic effects	43.84 mg/m3
	Consumers	Skin contact	Long-term systemic effects	12.61 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	12.61 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Glycerides, mixed decanoyl and octanoyl	Oral (Secondary Poisoning)	0.03 mg/kg food

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.1	28.09.2024	1228550-00022	Date of first issue: 18.01.2017

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment			
Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.	
Hand protection			
Material	:	Chemical-resistant gloves	
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.	
Respiratory protection	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387	
Filter type	:	Combined particulates and organic vapour type (A-P)	

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	liquid
Colour	:	light yellow
Odour	:	characteristic
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Vers 6.1	ion	Revision Date: 28.09.2024		S Number: 28550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017
	Flamm	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available	9
		explosion limit / Lower bility limit	:	No data available	2
	Flash p	point	:	No data available	9
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	рН		:	No data available	9
	Viscosi Visc	ty cosity, kinematic	:	No data available	9
	Solubili Wat	ity(ies) er solubility	:	insoluble	
	Partitio octanol	n coefficient: n- /water	:	Not applicable	
	Vapour	pressure	:	No data available	9
	Relativ	e density	:	No data available	9
	Density	/	:	0.90 - 0.94 g/cm ³	3
	Relativ	e vapour density	:	No data available	9
		e characteristics ticle size	:	Not applicable	
		oformation			
	Explosi	ves	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Evapor	ation rate	:	No data available	9
	Molecu	lar weight	:	No data available	9

Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
6.1		1228550-00022	Date of first issue: 18.01.2017

SECTION 10: Stability and reactivity

10.1 Posetivity

SECTION 11: Toxicological information						
No hazardous decomposition products are known.						
10.6 Hazardous decomposition products						
Materials to avoid : Oxidizing agents						
10.5 Incompatible materials						
Conditions to avoid : None known.						
10.4 Conditions to avoid						
Hazardous reactions : Can react with strong oxidizing agents.						
10.3 Possibility of hazardous reactions						
10.2 Chemical stability Stable under normal conditions.						
Not classified as a reactivity hazard.						
10.1 Reactivity						

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
Acute toxicity		
Harmful if inhaled.		
Product:		
Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: 2.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Components:		
abamectin (combination of a Acute oral toxicity		rmectin B1a and avermectin B1b) (ISO): LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version 6.1	Revision Date: 28.09.2024	•••	DS Number: 28550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017
Acute	e inhalation toxicity	:	LDLo (Monkey): Symptoms: Dilata LC50 (Rat): 0.02 Exposure time: 4 Test atmosphere	ation of the pupil 3 mg/l • h
Acute dermal toxicity		:	LD50 (Rat): 330 LD50 (Rabbit): 2	mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	:	Rabbit
Result	:	Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Result	:	Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version 6.1	Revision Date: 28.09.2024	SDS Number: 1228550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017			
		Result: negative	9			
		Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster lung cells Result: negative				
		Test Type: Alkaline elution assay Result: negative				
Genc	otoxicity in vivo	cytogenetic tes Species: Mouse	ite: Intraperitoneal injection			
	inogenicity					
Not c	lassified based on ava	ailable information.				

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	:	Rat
Application Route	:	Oral
Exposure time	:	105 weeks
Result	:	negative
		•
Species	:	Mouse
	:	Mouse Oral
Species Application Route Exposure time	:	

Reproductive toxicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility :	Test Type: Fertility Species: Rat, male Application Route: Oral Result: Effects on fertility
	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: NOAEL: 0.12 mg/kg body weight Result: Fetotoxicity
Effects on foetal develop- : ment	Test Type: Embryo-foetal development Species: Mouse Application Route: Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Versior 6.1	n Revision Date: 28.09.2024	SDS Number: 1228550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017
		Developmer Result: Cleft Remarks: A Test Type: E Species: Ra Application I Developmer Result: Cleft survival Remarks: A Test Type: E Species: Ra	dverse developmental effects were observed Embryo-foetal development bbit Route: Oral ntal Toxicity: LOAEL: 2 mg/kg body weight palate, Teratogenic effects, Reduced embryonic dverse developmental effects were observed Development t
			Route: Oral htal Toxicity: LOAEL: 1.6 mg/kg body weight togenic effects
	eproductive toxicity - As- essment	fertility, base	nce of adverse effects on sexual function and ed on animal experiments., Some evidence of ects on development, based on animal experi-

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes	:	Ingestion
Target Organs	:	Central nervous system
Assessment	:	Causes damage to organs through prolonged or repeated
		exposure.

Repeated dose toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	:	Rat
NOAEL	:	1.5 mg/kg
Application Route	:	Oral
Exposure time	:	24 Months
Target Organs	:	Central nervous system
Symptoms	:	Tremors, ataxia
Species NOAEL Application Route	:	Mouse 4.0 mg/kg Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version 6.1	Revision Date: 28.09.2024	SDS Number: 1228550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017
	sure time et Organs otoms	: 24 Months : Central nervou : Tremors, ataxi	•
Expo	EL EL cation Route sure time et Organs otoms	: Dog : 0.25 mg/kg : 0.5 mg/kg : Oral : 53 Weeks : Central nervou : Tremors, weig : mortality obse	htloss
Expo		: Monkey : 1.0 mg/kg : Oral : 14 Weeks : Central nervou	ıs system

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion

: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12: Ecological information

12.1 Toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 μg/l Exposure time: 96 h
		LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 μ g/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Versic 6.1	on	Revision Date: 28.09.2024		DS Number: 28550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017
				Exposure time: 9	6 h
				LC50 (Ictalurus p Exposure time: 9	unctatus (channel catfish)): 24 μg/l δ h
				LC50 (Cyprinus o Exposure time: 9	arpio (Carp)): 42 μg/l δ h
				LC50 (Cyprinodo Exposure time: 9	n variegatus (sheepshead minnow)): 15 µg/l 6 h
		to daphnia and other invertebrates	:	EC50 (Americam Exposure time: 9	
				EC50 (Daphnia n Exposure time: 4	nagna (Water flea)): 0.34 µg/l 8 h
	oxicity lants	/ to algae/aquatic	:	EC50 (Pseudokir mg/l Exposure time: 72	chneriella subcapitata (green algae)): 100 2 h
	/I-Fact city)	or (Acute aquatic tox-	:	10,000	
Т	oxicity	<i>i</i> to microorganisms	:	EC50 : > 1,000 m Exposure time: 3 Test Type: Respi	ĥ
	oxicity city)	/ to fish (Chronic tox-	:	NOEC: 0.52 µg/l Exposure time: 3 Species: Pimeph	2 d ales promelas (fathead minnow)
а		/ to daphnia and other invertebrates (Chron- ity)		NOEC: 0.03 µg/l Exposure time: 2 Species: Daphnia	1 d a magna (Water flea)
				NOEC: 0.0035 µg Exposure time: 2 Species: Mysidop	
	/I-Fact oxicity	or (Chronic aquatic)	:	10,000	
12.2 F	Persis	tence and degradabil	ity		
<u>C</u>	compo	onents:			
_	homo	atin (combination of		rmaatin Dia and	avermentin B1b) (ISO):

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

S MSD 🛕 Public

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.1	28.09.2024	1228550-00022	Date of first issue: 18.01.2017

12.3 Bioaccumulative potential

Components:

abamectin (combination	of avermectin B1a and avermectin B1b) (ISO):
Disconstructure	Discourse stration factor (DOF), 50

Bioaccumulation	:	Bioconcentration factor (BCF): 52

Partition coefficient: n-	:	log Pow: 4
octanol/water		-

12.4 Mobility in soil

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environ-	:	log Koc: > 3.6
mental compartments		

12.5 Results of PBT and vPvB assessment

Ρ	r	0	d	u	С	t	:	

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

i i ouuci.	P	r	^	d		c	t٠
			v	u	u	c	ι.

REACH Article 57(f) or Commission Delegated regulation	Assessment	:	(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at
--	------------	---	--

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Ρ

Product :	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Contaminated packaging :	 Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Abamectin Liquid Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
6.1		1228550-00022	Date of first issue: 18.01.2017
0.1	20:00:2021	1220000 00022	Bate et met 1864et. 18:01:2011

SECTION 14: Transport information

14.1 UN number or ID number			
ADN	:	UN 3082	
ADR	:	UN 3082	
RID	:	UN 3082	
IMDG	:	UN 3082	
ΙΑΤΑ	:	UN 3082	
14.2 UN proper shipping name			
ADN	:	N.O.S.	HAZARDOUS SUBSTANCE, LIQUID, on of avermectin B1a and avermectin
ADR	:	N.O.S.	HAZARDOUS SUBSTANCE, LIQUID, on of avermectin B1a and avermectin
RID	:	N.O.S.	HAZARDOUS SUBSTANCE, LIQUID, on of avermectin B1a and avermectin
IMDG	:	N.O.S.	HAZARDOUS SUBSTANCE, LIQUID, on of avermectin B1a and avermectin
ΙΑΤΑ	:		dous substance, liquid, n.o.s. on of avermectin B1a and avermectin
14.3 Transport hazard class(es)			
		Class	Subsidiary risks
ADN	:	9	
ADR	:	9	

ADN	•	9
ADR	:	9
RID	:	9
IMDG	:	9
ΙΑΤΑ	:	9
14.4 Packing group		
ADN Packing group Classification Code Hazard Identification Number Labels	: : :	III M6 90 9

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Vers 6.1	ion	Revision Date: 28.09.2024		9S Number: 28550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017
	Hazard Labels	g group cation Code Identification Number restriction code		III M6 90 9 (-)	
		g group cation Code Identification Number	: : :	III M6 90 9	
	IMDG Packing Labels EmS Co		:	III 9 F-A, S-F	
	aircraft)	g instruction (cargo	:	964 Y964 III Miscellaneous	
	Packing ger airc	g instruction (LQ)	:	964 Y964 III Miscellaneous	
14.5	Enviro	nmental hazards			
	ADN Environ	mentally hazardous	:	yes	
	ADR Environ	mentally hazardous	:	yes	
	RID Environ	mentally hazardous	:	yes	
	IMDG Marine	pollutant	:	yes	
		Passenger) mentally hazardous	:	yes	
	IATA ((Environ	Cargo) mentally hazardous	:	yes	
116	Snaaia	I propoutions for use	~		

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.1	28.09.2024	1228550-00022	Date of first issue: 18.01.2017

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislat ture	tion	specific for the substance or mix-
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 3
		Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not.
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parlian		t and of the Council on the control of

major-accident hazards involving dangerous substances. _

	g dangerede edbetaneeer	Quantity 1	Quantity 2
E1	ENVIRONMENTAL HAZARDS	100 t	200 t

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
------	---	----------------

DSL : not determined according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version 6.1	Revision Date: 28.09.2024	SDS Number: 1228550-00022	Date of last issue: 06.04.2024 Date of first issue: 18.01.2017	
IECS	С	: not determined		
15.2 Chen	nical safety assessme	nt		
A Chemica	al Safety Assessment h	as not been carried ou	t.	
SECTION	16: Other informat	on		
Other	niformation		nges have been made to the previous version the body of this document by two vertical	
Full t	ext of H-Statements			
H300 H311 H330 H361		 Fatal if swallowe Toxic in contact v Fatal if inhaled. Suspected of dar unborn child. 		
H372 H400		: Causes damage exposure if swall	 Causes damage to organs through prolonged or repeated exposure if swallowed. Very toxic to aquatic life. 	
H400 H410			Very toxic to aquatic life with long lasting effects.	
Full t	ext of other abbreviat	ons		
	tic Acute tic Chronic	: Long-term (chror : Reproductive tox	e) aquatic hazard nic) aquatic hazard icity gan toxicity - repeated exposure	

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency: EC-Number - European Community number: ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
6.1	28.09.2024	1228550-00022	Date of first issue: 18.01.2017

Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data Sheet	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification procedure:

Classification of the mixture:

Acute Tox. 4	H332	Calculation method
STOT RE 2	H373	Calculation method
Aquatic Acute 1	H400	Calculation method
Aquatic Chronic 1	H410	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN